Amphastar Delivers Strong Quarter With Epinephrine Gains
As Company’s US Glucagon Rival Performs Well
Amphastar delivers back-to-back strong quarters as the company continues to see a rise in sales of its key products including Primatene Mist (epinephrine), glucagon and other epinephrine products. The company continues to build its pipeline and diversify its portfolio.
You may also be interested in...
Amphastar has secured the first US approval for a generic version of Eli Lilly’s glucagon emergency kit.
US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.
India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets.